High efficiency differentiation of human pluripotent stem cells to cardiomyocytes and characterization by flow cytometry

Subarna Bhattacharya, Paul W. Burridge, Erin M. Kropp, Sandra L. Chuppa, Wai Meng Kwok, Joseph C. Wu, Kenneth R. Boheler, Rebekah L. Gundry

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

There is an urgent need to develop approaches for repairing the damaged heart, discovering new therapeutic drugs that do not have toxic effects on the heart, and improving strategies to accurately model heart disease. The potential of exploiting human induced pluripotent stem cell (hiPSC) technology to generate cardiac muscle “in a dish” for these applications continues to generate high enthusiasm. In recent years, the ability to efficiently generate cardiomyogenic cells from human pluripotent stem cells (hPSCs) has greatly improved, offering us new opportunities to model very early stages of human cardiac development not otherwise accessible. In contrast to many previous methods, the cardiomyocyte differentiation protocol described here does not require cell aggregation or the addition of Activin A or BMP4 and robustly generates cultures of cells that are highly positive for cardiac troponin I and T (TNNI3, TNNT2), iroquois-class homeodomain protein IRX-4 (IRX4), myosin regulatory light chain 2, ventricular/cardiac muscle isoform (MLC2v) and myosin regulatory light chain 2, atrial isoform (MLC2a) by day 10 across all human embryonic stem cell (hESC) and hiPSC lines tested to date. Cells can be passaged and maintained for more than 90 days in culture. The strategy is technically simple to implement and cost-effective. Characterization of cardiomyocytes derived from pluripotent cells often includes the analysis of reference markers, both at the mRNA and protein level. For protein analysis, flow cytometry is a powerful analytical tool for assessing quality of cells in culture and determining subpopulation homogeneity. However, technical variation in sample preparation can significantly affect quality of flow cytometry data. Thus, standardization of staining protocols should facilitate comparisons among various differentiation strategies. Accordingly, optimized staining protocols for the analysis of IRX4, MLC2v, MLC2a, TNNI3, and TNNT2 by flow cytometry are described.

Original languageEnglish (US)
Article numbere52010
JournalJournal of Visualized Experiments
Issue number91
DOIs
StatePublished - Sep 23 2014

Fingerprint

Pluripotent Stem Cells
Myosin Light Chains
Flow cytometry
Stem cells
Cardiac Myocytes
Induced Pluripotent Stem Cells
Flow Cytometry
Protein Isoforms
Efficiency
Myocardium
Cell Culture Techniques
Proteins
Staining and Labeling
Homeodomain Proteins
Muscle
Cell Aggregation
Troponin T
Aptitude
Troponin I
Poisons

Keywords

  • Cardiomyocyte
  • Cellular Biology
  • Directed differentiation
  • Flow cytometry
  • Human induced pluripotent stem cell
  • IRX4
  • Issue 91
  • MCL2v
  • MLC2a
  • TNNI3
  • TNNT2

ASJC Scopus subject areas

  • Neuroscience(all)
  • Chemical Engineering(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

High efficiency differentiation of human pluripotent stem cells to cardiomyocytes and characterization by flow cytometry. / Bhattacharya, Subarna; Burridge, Paul W.; Kropp, Erin M.; Chuppa, Sandra L.; Kwok, Wai Meng; Wu, Joseph C.; Boheler, Kenneth R.; Gundry, Rebekah L.

In: Journal of Visualized Experiments, No. 91, e52010, 23.09.2014.

Research output: Contribution to journalArticle

Bhattacharya, Subarna ; Burridge, Paul W. ; Kropp, Erin M. ; Chuppa, Sandra L. ; Kwok, Wai Meng ; Wu, Joseph C. ; Boheler, Kenneth R. ; Gundry, Rebekah L. / High efficiency differentiation of human pluripotent stem cells to cardiomyocytes and characterization by flow cytometry. In: Journal of Visualized Experiments. 2014 ; No. 91.
@article{6c898138bf724942ba15c700b30654df,
title = "High efficiency differentiation of human pluripotent stem cells to cardiomyocytes and characterization by flow cytometry",
abstract = "There is an urgent need to develop approaches for repairing the damaged heart, discovering new therapeutic drugs that do not have toxic effects on the heart, and improving strategies to accurately model heart disease. The potential of exploiting human induced pluripotent stem cell (hiPSC) technology to generate cardiac muscle “in a dish” for these applications continues to generate high enthusiasm. In recent years, the ability to efficiently generate cardiomyogenic cells from human pluripotent stem cells (hPSCs) has greatly improved, offering us new opportunities to model very early stages of human cardiac development not otherwise accessible. In contrast to many previous methods, the cardiomyocyte differentiation protocol described here does not require cell aggregation or the addition of Activin A or BMP4 and robustly generates cultures of cells that are highly positive for cardiac troponin I and T (TNNI3, TNNT2), iroquois-class homeodomain protein IRX-4 (IRX4), myosin regulatory light chain 2, ventricular/cardiac muscle isoform (MLC2v) and myosin regulatory light chain 2, atrial isoform (MLC2a) by day 10 across all human embryonic stem cell (hESC) and hiPSC lines tested to date. Cells can be passaged and maintained for more than 90 days in culture. The strategy is technically simple to implement and cost-effective. Characterization of cardiomyocytes derived from pluripotent cells often includes the analysis of reference markers, both at the mRNA and protein level. For protein analysis, flow cytometry is a powerful analytical tool for assessing quality of cells in culture and determining subpopulation homogeneity. However, technical variation in sample preparation can significantly affect quality of flow cytometry data. Thus, standardization of staining protocols should facilitate comparisons among various differentiation strategies. Accordingly, optimized staining protocols for the analysis of IRX4, MLC2v, MLC2a, TNNI3, and TNNT2 by flow cytometry are described.",
keywords = "Cardiomyocyte, Cellular Biology, Directed differentiation, Flow cytometry, Human induced pluripotent stem cell, IRX4, Issue 91, MCL2v, MLC2a, TNNI3, TNNT2",
author = "Subarna Bhattacharya and Burridge, {Paul W.} and Kropp, {Erin M.} and Chuppa, {Sandra L.} and Kwok, {Wai Meng} and Wu, {Joseph C.} and Boheler, {Kenneth R.} and Gundry, {Rebekah L.}",
year = "2014",
month = "9",
day = "23",
doi = "10.3791/52010",
language = "English (US)",
journal = "Journal of Visualized Experiments",
issn = "1940-087X",
publisher = "MYJoVE Corporation",
number = "91",

}

TY - JOUR

T1 - High efficiency differentiation of human pluripotent stem cells to cardiomyocytes and characterization by flow cytometry

AU - Bhattacharya, Subarna

AU - Burridge, Paul W.

AU - Kropp, Erin M.

AU - Chuppa, Sandra L.

AU - Kwok, Wai Meng

AU - Wu, Joseph C.

AU - Boheler, Kenneth R.

AU - Gundry, Rebekah L.

PY - 2014/9/23

Y1 - 2014/9/23

N2 - There is an urgent need to develop approaches for repairing the damaged heart, discovering new therapeutic drugs that do not have toxic effects on the heart, and improving strategies to accurately model heart disease. The potential of exploiting human induced pluripotent stem cell (hiPSC) technology to generate cardiac muscle “in a dish” for these applications continues to generate high enthusiasm. In recent years, the ability to efficiently generate cardiomyogenic cells from human pluripotent stem cells (hPSCs) has greatly improved, offering us new opportunities to model very early stages of human cardiac development not otherwise accessible. In contrast to many previous methods, the cardiomyocyte differentiation protocol described here does not require cell aggregation or the addition of Activin A or BMP4 and robustly generates cultures of cells that are highly positive for cardiac troponin I and T (TNNI3, TNNT2), iroquois-class homeodomain protein IRX-4 (IRX4), myosin regulatory light chain 2, ventricular/cardiac muscle isoform (MLC2v) and myosin regulatory light chain 2, atrial isoform (MLC2a) by day 10 across all human embryonic stem cell (hESC) and hiPSC lines tested to date. Cells can be passaged and maintained for more than 90 days in culture. The strategy is technically simple to implement and cost-effective. Characterization of cardiomyocytes derived from pluripotent cells often includes the analysis of reference markers, both at the mRNA and protein level. For protein analysis, flow cytometry is a powerful analytical tool for assessing quality of cells in culture and determining subpopulation homogeneity. However, technical variation in sample preparation can significantly affect quality of flow cytometry data. Thus, standardization of staining protocols should facilitate comparisons among various differentiation strategies. Accordingly, optimized staining protocols for the analysis of IRX4, MLC2v, MLC2a, TNNI3, and TNNT2 by flow cytometry are described.

AB - There is an urgent need to develop approaches for repairing the damaged heart, discovering new therapeutic drugs that do not have toxic effects on the heart, and improving strategies to accurately model heart disease. The potential of exploiting human induced pluripotent stem cell (hiPSC) technology to generate cardiac muscle “in a dish” for these applications continues to generate high enthusiasm. In recent years, the ability to efficiently generate cardiomyogenic cells from human pluripotent stem cells (hPSCs) has greatly improved, offering us new opportunities to model very early stages of human cardiac development not otherwise accessible. In contrast to many previous methods, the cardiomyocyte differentiation protocol described here does not require cell aggregation or the addition of Activin A or BMP4 and robustly generates cultures of cells that are highly positive for cardiac troponin I and T (TNNI3, TNNT2), iroquois-class homeodomain protein IRX-4 (IRX4), myosin regulatory light chain 2, ventricular/cardiac muscle isoform (MLC2v) and myosin regulatory light chain 2, atrial isoform (MLC2a) by day 10 across all human embryonic stem cell (hESC) and hiPSC lines tested to date. Cells can be passaged and maintained for more than 90 days in culture. The strategy is technically simple to implement and cost-effective. Characterization of cardiomyocytes derived from pluripotent cells often includes the analysis of reference markers, both at the mRNA and protein level. For protein analysis, flow cytometry is a powerful analytical tool for assessing quality of cells in culture and determining subpopulation homogeneity. However, technical variation in sample preparation can significantly affect quality of flow cytometry data. Thus, standardization of staining protocols should facilitate comparisons among various differentiation strategies. Accordingly, optimized staining protocols for the analysis of IRX4, MLC2v, MLC2a, TNNI3, and TNNT2 by flow cytometry are described.

KW - Cardiomyocyte

KW - Cellular Biology

KW - Directed differentiation

KW - Flow cytometry

KW - Human induced pluripotent stem cell

KW - IRX4

KW - Issue 91

KW - MCL2v

KW - MLC2a

KW - TNNI3

KW - TNNT2

UR - http://www.scopus.com/inward/record.url?scp=84908292226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908292226&partnerID=8YFLogxK

U2 - 10.3791/52010

DO - 10.3791/52010

M3 - Article

C2 - 25286293

AN - SCOPUS:84908292226

JO - Journal of Visualized Experiments

JF - Journal of Visualized Experiments

SN - 1940-087X

IS - 91

M1 - e52010

ER -